1例肺鳞癌化疗诱发糖尿病的案例分析

A case analysis of chemotherapy-induced diabetes mellitus in one lung squamous cell carcinoma

目的:探讨肺鳞癌化疗后诱发糖尿病的原因及临床药师干预的意义。方法:对1例肺鳞癌cT_4N_3M_1Ⅲb期吉西他滨联合顺铂(GP方案)化疗后诱发糖尿病的病例进行分析。结果:化疗用药是导致该患者糖尿病发生的主要原因,临床药师积极参与肿瘤患者化疗用药的方案制定、疗效和不良反应监测十分必要,有利于改善患者的综合预后。结论:肺鳞癌患者化疗期间应注意监测血糖变化,及时调整治疗方案,必要时给予降糖治疗,并充分发挥临床药师在药物治疗中的作用,有利于改善患者愈后。

Objective：To investigate the causes of diabetes mellitus induced by chemotherapy in treatment of lung squamous cell carcinoma and the role of clinical pharmacists intervention.Methods：a case of diabetes induced by gemcitabine combined with cisplatin （GP regimen） chemotherapy in patient with lung squamous cell carcinoma cT4N3MⅢ b was analyzed.Results：Chemotherapy was the leading cause of diabetes in that patient.It is necessary for clinical pharmacists to actively participate in the formulation,efficacy and adverse reaction monitoring of chemotherapy in patients with cancer.It is beneficial to improve the comprehensive prognosis of the patients.Conclusion：Patients with lung squamous cell carcinoma during chemotherapy should pay attention to monitoring blood glucose changes,timely adjustment of treatment programs,if necessary,given hypoglycemic treatment,and give full play to the role of clinical pharmacists in drug therapy,all above would help improve the prognosis of patients.